Alnylam Pharmaceuticals | ALNY - Trade Debtors


Alnylam Pharmaceuticals reported $912.74M in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amgen USD 10.23B 1.09B Jun/2026
Arrowhead Research USD 8.56M 7.13M Jun/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Incyte USD 1.13B 73.7M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
Moderna USD 17M 54M Jun/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Novartis USD 9.6B 2.69B Mar/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Takeda JPY 956.14B 79.79B Jun/2026
Tectonic Therapeutic USD 0 270K Dec/2023
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026
Xencor USD 42.23M 30.23M Jun/2026